Related Experiment Video
Updated: Jan 17, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Titrating Cabozantinib in Metastatic Renal Cell Carcinoma Patients Using Goldilocks Principle: A Real-World Evidence
Malou Aarønæs Thybo1, Johanne Ahrenfeldt2, Iben Lyskjær2
1Department of Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Introduction:
The incidence of renal cell carcinoma (RCC) continues to rise worldwide, and this malignancy has demonstrated substantial sensitivity to both immunotherapies and targeted agents, particularly tyrosine kinase inhibitors (TKIs). Cabozantinib, a commonly utilized TKI, has shown promising efficacy across multiple clinical trials. This study aims to evaluate the real-world effectiveness of individualized cabozantinib dosing as a later-line treatment in patients with metastatic RCC (mRCC).
Patients And Methods:
Patients with mRCC treated at the Department of Oncology, Aarhus University Hospital, Denmark, were identified to estimate the median progression free survival (mPFS) and median overall survival (mOS) from treatment initiation. Best radiological response was evaluated using RECIST 1.1. Multivariable cox regression analyses were performed, including covariates such as brain metastasis, first-line treatment, line of treatment, ECOG Performance Status, IMDC risk group, nephrectomy status, and toxicity.
Results:
A total of 179 patients were included, of which 139 patients received second-line (2L) treatment, and 40 patients received third+-line (3+L) treatment. We found a mPFS of 11.2 months for 2L treatment and 11.6 months for 3+L treatment. The mOS was 15.6 months for the 2L group and 17.1 months for the 3+L group. The mPFS and mOS in the IMDC favourable risk group were 28.5 and 52.1 months, respectively. No significant differences in mPFS or mOS were observed based on prior 1L treatment or the presence of brain metastases. The mOS and mPFS found in this study are comparable to, and in some cases exceed, those reported in other real-world cohorts. Interestingly, we found treatment-related toxicity to correlate significantly with an increased survival (mOS 24.7 vs. 12.2 months, P = .022) (mPFS 14,7 vs. 8,5 months, P = .013).
Conclusion:
This study reinforces the existing data on effectiveness of cabozantinib as a later-line treatment for mRCC in real-world settings. We report 40 mg as the preferred landing zone. Furthermore we identify patients needing dose reductions due to toxicity as a subgroup carrying a significantly better prognosis. The results emphasize the importance of individual dosage for optimizing treatment outcomes and points out treatment-related toxicity as a surrogate marker for sufficient serum concentration of the active substance.
Insights
Individualized cabozantinib dosing is effective for metastatic renal cell carcinoma (mRCC) in real-world settings. Patients experiencing toxicity, often requiring dose reduction, showed significantly better prognosis, suggesting toxicity as a marker for optimal dosing.
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Rising incidence of renal cell carcinoma (RCC) globally.
- RCC demonstrates sensitivity to immunotherapies and tyrosine kinase inhibitors (TKIs).
- Cabozantinib is an effective TKI for metastatic RCC (mRCC).
Purpose of the Study:
- Evaluate real-world effectiveness of individualized cabozantinib dosing in later-line mRCC treatment.
- Assess progression-free survival (PFS) and overall survival (OS).
- Identify factors influencing treatment outcomes.
Main Methods:
- Retrospective analysis of 179 mRCC patients treated at Aarhus University Hospital.
- Estimation of median PFS (mPFS) and median OS (mOS).
- Multivariable Cox regression analysis including clinical covariates and toxicity.
Main Results:
- mPFS of 11.2 months (2L) and 11.6 months (3+L); mOS of 15.6 months (2L) and 17.1 months (3+L).
- Comparable or superior survival outcomes to existing real-world data.
- Treatment-related toxicity significantly correlated with increased survival (mOS 24.7 vs. 12.2 months, P=.022).
Conclusions:
- Reinforces cabozantinib's effectiveness in later-line mRCC treatment.
- Suggests 40 mg as a preferred cabozantinib dosage.
- Identifies patients requiring dose reduction due to toxicity as having a better prognosis, highlighting toxicity as a potential marker for sufficient drug concentration.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:25Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:15Bioavailability Study Design: Healthy Subjects Versus Patients